ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,037.10
0.37%
Dow Jones
38,046.98
0.38%
US Dollar vs MXN
16.92798
-0.09%
Brent Oil
83.335
-0.25%
Bitcoin
59,048.57
1.39%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aeglea BioTherapeutics Inc (AGLE)

  7. Aeglea BioTherapeutics Inc (AGLE) Noticias

AGLE Aeglea BioTherapeutics Inc

12.01
0.00 (0.00%)
Última actualización: 19:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Aeglea BioTherapeutics Inc AGLE NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 12.01 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
12.01
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
25/4/202415:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/4/202415:40EDGAR2Form SC 13D/A - General statement of acquisition of..
25/4/202415:21EDGAR2Form 8-K - Current report
01/4/202415:06EDGAR2Form DEF 14A - Other definitive proxy statements
20/3/202406:14EDGAR2Form PRE 14A - Other preliminary proxy statements
18/3/202415:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/3/202407:31EDGAR2Form 8-K - Current report
14/3/202415:12EDGAR2Form POS AM - Post-Effective amendments for registration..
28/11/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202306:33EDGAR2Form 8-K - Current report
27/11/202315:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202315:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202315:32EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/11/202315:27EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/11/202315:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202307:30PRNUSAeglea BioTherapeutics Announces Name Change to Spyre..
22/11/202319:45EDGAR2Form 8-K - Current report
22/11/202316:00PRNUSAeglea BioTherapeutics Announces Grants of Inducement Awards
15/11/202316:18EDGAR2Form S-1/A - General form for registration of securities..
15/11/202316:14EDGAR2Form 8-K - Current report
14/11/202314:13EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/11/202315:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:06EDGAR2Form 8-K - Current report
09/11/202315:05PRNUSAeglea BioTherapeutics Reports Third Quarter 2023 Financial..
03/11/202316:00PRNUSAeglea BioTherapeutics Announces Grants of Inducement Awards
30/10/202319:00PRNUSAeglea BioTherapeutics to Participate in Upcoming November..
26/10/202320:53EDGAR2Form DEF 14A - Other definitive proxy statements
24/10/202308:00EDGAR2Form 8-K - Current report
06/10/202320:40EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
05/10/202316:13EDGAR2Form 8-K - Current report
02/10/202317:02PRNUSAeglea BioTherapeutics Announces Grants of Inducement Awards
25/9/202315:02EDGAR2Form 8-K - Current report
14/9/202316:03PRNUSAeglea BioTherapeutics to Participate in Upcoming September..
08/9/202316:05EDGAR2Form 8-K - Current report
07/9/202307:40PRNUSAeglea BioTherapeutics Announces Reverse Stock Split
05/9/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202315:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202315:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202306:06EDGAR2Form 8-K - Current report
05/9/202306:00PRNUSAeglea BioTherapeutics Expands Executive Leadership Team..
11/8/202306:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202306:02EDGAR2Form 8-K - Current report
11/8/202306:01EDGAR2Form 8-K - Current report
11/8/202306:00PRNUSAeglea BioTherapeutics Reports Second Quarter 2023 Financial..
07/8/202320:51EDGAR2Form PRE 14A - Other preliminary proxy statements
07/8/202315:25EDGAR2Form S-3 - Registration statement under Securities Act of..
28/7/202308:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
27/7/202306:01EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
AGLE
Aeglea BioTherapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados